Collectively, these findings suggest that CK18 may serve as a promising biomarker reflecting disease activity and hepatic injury status in NAFLD and NASH, while also implicating a potential mechanistic link between hepatocyte apoptosis and cardiovascular involvement in this metabolic disorder. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatotic liver disease.